Neuren制药公司就缺氧缺血性脑病新药临床试验申请计划获监管反馈

美股速递
Feb 04

Neuren Pharmaceuticals Ltd(NEU.AU)近日宣布,已收到关于其针对缺氧缺血性脑病(HIE)的新药临床试验(IND)申请计划的相关反馈意见。

该反馈涉及公司计划向监管机构提交的IND申请的具体方案,标志着其在HIE治疗药物研发进程中迈出重要一步。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10